Click here to see the original post on AdPharm

Visit AdPharm.net for more pharmaceutical ads

Voici Abilify, indiqu?© dans le traitement de la schizophr?©nie.
Parce que les sympt??mes n?©gatifs font aussi partie de la route.

Une att?©nuation des sympt??mes positifs et n?©gatifs a ?©t?© d?©montr?©e avec Abilify.

Nouveau Abilify.

Here's Abilify, indicated for the treatment of schizophrenia.
Because negative symptoms are also part of the road.

New Abilify.

Aripiprazole (marketed as Abilify, Abilify Discmelt; also known as BMS 337039, OPC-14597, and APZ) was approved by the Food and Drug Administration (FDA) on November 15, 2002 for the treatment of schizophrenia, the sixth atypical antipsychotic medication of its kind. More recently, it received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder, and as an adjunct for the treatment of major depressive disorder. Aripiprazole was developed by Otsuka in Japan; in the U.S., Otsuka America markets the drug jointly with Bristol-Myers Squibb.

More on Wikipedia

Brand name: Abilify
Generic name/category: Aripiprazole, Atypical antipsychotics, Piperazines
Company: Bristol-Myers Squibb (BMS)
Country/Market: Canada, North America
Indication(s)/use: Schizophrenia
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: double-page spread
Publication/Aired: Le M?©decin du Qu?©bec – September 2009

To see all of this brand's ads on AdPharm, click here
0 views
Sep 09, 2009

Visit AdPharm.net for more pharmaceutical ads